Clinical trials: Peanut Allergic Subjects
Peanut Allergy
Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects
This phase I clinical trial is designed to evaluate the safety and tolerability of VLP Peanut in healthy subjects and in subjects with peanut allergy (PA).
- Trial name
- PROTECT (NCT05476497)
- Testing
- VLP Peanut
- Where
- 10 sites in United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Allergy Therapeutics
Peanut Allergy
A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects
The study aims to assess the biological potency of the In-House Reference Preparation (IHRP) of peanut allergens extract by a quantitative Skin Prick Test (SPT) method in peanut-allergic subjects.
- Trial name
- V712-103 (NCT03352726)
- Testing
- DBV712 IHRP
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- DBV Technologies
Food Hypersensitivity, Hypersensitivity
Peanut Allergy Vaccine Study in Healthy and Peanut-allergic Adults
The purpose of this study is to evaluate the safety and side effects of a study product that contains recombinant modified peanut proteins (EMP-123) in healthy and peanut-allergic participants. This is a first in human study.
- Conditions
- Food Hypersensitivity, Hypersensitivity, Immediate Hypersensitivity, Peanut Hypersensitivity
- Trial name
- NCT00850668
- Testing
- E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3
- Where
- 2 sites in United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Allertein Therapeutics, LLC
Peanut Hypersensitivity
A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g
This is a Phase IIb, multicenter, open-label study available to active (Xolair) and control (placebo) subjects who have completed their final visit (or early termination visit, if applicable) for Study Q2788g, who meet the…
- Trial name
- NCT00382148
- Testing
- omalizumab
- Volunteers
- 11 people
- Sponsor
- Genentech, Inc.
Peanut Allergy
Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)
The purpose of this study is to assess AR101's safety, tolerability and efficacy over an extended dosing period.
- Trial name
- NCT03292484
- Testing
- AR101
- Where
- 93 sites in United States, Canada and 8 more
- Volunteers
- 911 people
- Sponsor
- Aimmune Therapeutics, Inc.